ERBB2 and inflammatory breast carcinoma: The BEVERLY-1 (UCBG-0802) trial was a phase 2, single-arm trial, in which women with non-metastatic HER2- IBC were treated with neoadjuvant intravenous fluorouracil (500 mg/m2), epirubicin (100 mg/m2), cyclophosphamide (500 mg/m2), and bevacizumab (15 mg/kg) during cycles 1–4 (21 days-cycle), then docetaxel (100 mg/m2) and bevacizumab during cycles 5–8 [78].